In April 2010, sipuleucel-T (Provenge ... without substantial side effects 5. However, near-term challenges of manufacturing this autologous immunotherapy for each patient and its high cost ...

Provenge (sipuleucel-T) is an autologous cellular immunotherapy, which involves removing immune cells from a patient's blood, priming them to recognise prostate cancer, and then returning them to ...

The two trials randomized patients 2:1 to receive either sipuleucel-T immunotherapy—autologous peripheral blood mononuclear cells loaded with a recombinant fusion protein comprising prostatic ...

There is little to no evidence these unregulated products work and can cause serious side effects ... cell therapy called Provenge (sipuleucel-T), which received marketing authorisation in ...